Baker McKenzie Advised SPE Capital-led Consortium On Investment In Orchidia Pharmaceutical Industries
Baker McKenzie advised SPE Capital-led consortium on investment in Orchidia Pharma across MENA region
Baker McKenzie advised SPE Capital-led Consortium on Investment in Orchidia Pharmaceutical Industries
The Global alw firm, Baker McKenzie advised a consortium of investors led by SPE Capital, through its Private Equity Fund III (PEF III), on its investment in a European holding company, the parent company of Orchidia Pharmaceutical Industries S.A.E., a leading ophthalmic pharmaceutical manufacturer with operations in Egypt and across the Middle East and Africa. The transaction was successfully completed in March 2026.
The investor consortium included the European Bank for Reconstruction and Development (EBRD), Société de Promotion et de Participation pour la Coopération Économique (Proparco), and the Belgian Investment Company for Developing Countries (BIO). Baker McKenzie acted as lead counsel on the transaction, advising across all aspects including investment structuring, consortium arrangements, due diligence, documentation, signing and completion across multiple jurisdictions.
Hani Nassef, Partner at Baker McKenzie, said,
“We were pleased to support SPE Capital and the investor consortium on this strategically important transaction, drawing on our experience in complex private equity investments in the pharma sector across multiple jurisdictions,”
The Baker McKenzie team was led by Hani Nassef (Partner), with support from Zeinab Shohdy, Ingy Elkady, Hala Mohamed, Hayna Abdelrehim, Chirouette Elmasry, Noureldin El Hayatmy and Hanna Ahmed. Antitrust advice was provided by Mohamed Elfar, Hania Negm and Mohamed Elbaroudy.
Click to know more about Baker McKenzie
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.